Top

Published in:

01-09-2008 | Epidemiology

The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study

Authors: Bernd Frank, Sushila H. Rigas, Justo Lorenzo Bermejo, Miriam Wiestler, Kerstin Wagner, Kari Hemminki, Malcolm W. Reed, Christian Sutter, Barbara Wappenschmidt, Sabapathy P. Balasubramanian, Alfons Meindl, Marion Kiechle, Peter Bugert, Rita K. Schmutzler, Claus R. Bartram, Christina Justenhoven, Yon-Dschun Ko, Thomas Brüning, Hiltrud Brauch, Ute Hamann, Paul P. D. Pharoah, Alison M. Dunning, Karen A. Pooley, Douglas F. Easton, Angela Cox, Barbara Burwinkel

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

A recent study on an Asian population reported a six-nucleotide insertion-deletion polymorphism (-652 6N del) in the CASP8 promoter region to be strongly associated with a decreased risk of multiple types of cancer, including breast cancer (BC). Here, we investigate the effect of this deletion in four independent large European BC case-control studies, including data from a total of 7,753 cases and 7,921 controls. The combined per allele odds ratio (OR) was 0.97 (95% confidence interval (CI), 95% CI = 0.93–1.02). The present result indicates that the CASP8 -652 6N del variant has no significant effect on BC risk in Europeans.

Pharoah PD, Antoniou A, Bobrow M et al (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31:33–36PubMedCrossRef

Cox A, Dunning AM, Garcia-Closas M et al (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352–358PubMedCrossRef

Frank B, Hemminki K, Wappenschmidt B et al (2006) Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis 27:606–609PubMedCrossRef

Frank B, Bermejo JL, Hemminki K et al (2005) Re: association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 97:1012PubMed

MacPherson G, Healey CS, Teare MD et al (2004) Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 96:1866–1869PubMedCrossRef

Sun T, Gao Y, Tan W et al (2007) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39:605–613PubMedCrossRef

Rafii S, O’Regan P, Xinarianos G et al (2002) A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet 11:1433–1438PubMedCrossRef

Justenhoven C, Hamann U, Schubert F et al (2007) Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat, doi: 10.1007/s10549-007-9586-8

Pesch B, Ko Y, Brauch H et al (2005) Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 20:699–711PubMedCrossRef

10.

Baynes C, Healey CS, Pooley KA et al (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9:R27PubMedCrossRef

11.

Riboli E, Hunt KJ, Slimani N et al (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113–1124PubMedCrossRef

12.

Day N, Oakes S, Luben R et al (1999) EPIC-Norfolk: study design and characteristics of the cohort. European prospective investigation of cancer. Br J Cancer 80(Suppl 1):95–103PubMed

13.

Wagner K, Hemminki K, Israelsson E et al (2005) Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer. Breast Cancer Res Treat 92:133–140PubMedCrossRef

14.

Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348PubMedCrossRef

15.

Hengartner MO (2000) The biochemistry of apoptosis. Nature 407:770–776PubMedCrossRef

16.

Ho PK, Hawkins CJ (2005) Mammalian initiator apoptotic caspases. Mammalian initiator apoptotic caspases. FEBS J 272:5436–5453PubMedCrossRef

17.

Siegel RM (2006) Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol 6:308–317PubMedCrossRef

18.

Soung YH, Lee JW, Kim SY et al (2005) CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res 65:815–821PubMed

19.

Liedtke C, Groger N, Manns MP, Trautwein C (2003) The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J Biol Chem 278:27593–27604PubMedCrossRef

20.

Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JP (2005) Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med 2:e334PubMedCrossRef

Title: The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study
Authors: Bernd Frank
Sushila H. Rigas
Justo Lorenzo Bermejo
Miriam Wiestler
Kerstin Wagner
Kari Hemminki
Malcolm W. Reed
Christian Sutter
Barbara Wappenschmidt
Sabapathy P. Balasubramanian
Alfons Meindl
Marion Kiechle
Peter Bugert
Rita K. Schmutzler
Claus R. Bartram
Christina Justenhoven
Yon-Dschun Ko
Thomas Brüning
Hiltrud Brauch
Ute Hamann
Paul P. D. Pharoah
Alison M. Dunning
Karen A. Pooley
Douglas F. Easton
Angela Cox
Barbara Burwinkel
Publication date: 01-09-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9752-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Old masters as clinical photographers: multifocal breast cancer diagnosed 400 years ago

Association of polymorphisms of angiogenesis genes with breast cancer

Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR

Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer

Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer

The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer